Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
Auvinen A, Tammela TLJ, Mirtti T, Lilja H, Tolonen T, Kenttämies A, Rinta-Kiikka I, Lehtimäki T, Natunen K, Nevalainen J, Raitanen J, Ronkainen J, van der Kwast T, Riikonen J, Pétas A, Matikainen M, Taari K, Kilpeläinen T, Rannikko AS; ProScreen Trial Investigators. Auvinen A, et al. Among authors: mirtti t. JAMA. 2024 May 7;331(17):1452-1459. doi: 10.1001/jama.2024.3841. JAMA. 2024. PMID: 38581254 Clinical Trial.
Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study.
Hietikko R, Kilpeläinen TP, Kenttämies A, Ronkainen J, Ijäs K, Lind K, Marjasuo S, Oksala J, Oksanen O, Saarinen T, Savolainen R, Taari K, Tammela TLJ, Mirtti T, Natunen K, Auvinen A, Rannikko A. Hietikko R, et al. Among authors: mirtti t. Cancer Imaging. 2020 Oct 9;20(1):72. doi: 10.1186/s40644-020-00351-w. Cancer Imaging. 2020. PMID: 33036660 Free PMC article.
Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study.
Rannikko A, Leht M, Mirtti T, Kenttämies A, Tolonen T, Rinta-Kiikka I, Kilpeläinen TP, Natunen K, Lilja H, Lehtimäki T, Raitanen J, Kujala P, Ronkainen J, Matikainen M, Petas A, Taari K, Tammela T, Auvinen A. Rannikko A, et al. Among authors: mirtti t. BJU Int. 2022 Aug;130(2):193-199. doi: 10.1111/bju.15683. Epub 2022 Jan 8. BJU Int. 2022. PMID: 34958531 Free PMC article. Clinical Trial.
Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study.
Hietikko R, Mirtti T, Kilpeläinen TP, Tolonen T, Räisänen-Sokolowski A, Nordling S, Hannus J, Laurila M, Taari K, Tammela TLJ, Autio R, Natunen K, Auvinen A, Rannikko A. Hietikko R, et al. Among authors: mirtti t. World J Urol. 2024 Apr 6;42(1):217. doi: 10.1007/s00345-024-04898-2. World J Urol. 2024. PMID: 38581590 Free PMC article.
Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy.
Sandeman K, Eineluoto JT, Pohjonen J, Erickson A, Kilpeläinen TP, Järvinen P, Santti H, Petas A, Matikainen M, Marjasuo S, Kenttämies A, Mirtti T, Rannikko A. Sandeman K, et al. Among authors: mirtti t. PLoS One. 2020 Jul 9;15(7):e0235779. doi: 10.1371/journal.pone.0235779. eCollection 2020. PLoS One. 2020. PMID: 32645056 Free PMC article.
Repeat multiparametric MRI in prostate cancer patients on active surveillance.
Eineluoto JT, Järvinen P, Kenttämies A, Kilpeläinen TP, Vasarainen H, Sandeman K, Erickson A, Mirtti T, Rannikko A. Eineluoto JT, et al. Among authors: mirtti t. PLoS One. 2017 Dec 27;12(12):e0189272. doi: 10.1371/journal.pone.0189272. eCollection 2017. PLoS One. 2017. PMID: 29281647 Free PMC article.
116 results